Skip to main content
Erschienen in: Breast Cancer 5/2018

12.03.2018 | Original Article

Characterization of an in vitro model system to explore control of tumor invasion of EMT6 and 4THM breast tumors by CD200:CD200R interactions

verfasst von: Reginald M. Gorczynski, Nuray Erin, Tahir Maqbool, Christopher P. Gorczynski, Laura Y. Gorczynski

Erschienen in: Breast Cancer | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and purpose

In BALB/c mice with transplantable breast tumors, we showed that CD200R1KO mice were cured of local and metastatic growth of EMT6 cells following surgical resection of localized tumor and immunization with irradiated cells along with CpG as adjuvant. On the other hand, wild-type (WT) animals treated in the same fashion develop pulmonary and liver metastases within 20 days of surgery. To develop an in vitro system which would mimic the in vivo model and allow exploration of factors controlling tumor invasion as a precursor to in vivo metastasis, we have developed and characterized a two-phase culture system.

Methods

Bone marrow mesenchymal stromal cells (BMMSCs) from WT, CD200KO or CD200R1KO mice were admixed with T lymphocytes from tumor-immunized mice and cultured in collagen gels. Tumor cells were subsequently seeded in fresh medium above this gel 1d later. We then investigated the regulation of tumor invasion from the liquid to the gel layer. Tumor cells were measured in the gel layer following collagenase digestion and cultured at limiting dilution—an aliquot of the digest was also analyzed for cytokine levels in ELISA.

Results

BMMSCs from WT, CD200KO and CD200R1KO mice all augmented seeding/growth of EMT6 and 4THM tumor cells into the collagen matrix. Inclusion of IL-6 and IL-17 in the gel matrix was associated with increased invasion of tumor cells into this layer. Inclusion of DLN cells from EMT6 immune or 4THM immune mice further modified tumor invasion, with increased tumor numbers seen using stromal elements from CD200 and CD200R1KO mice and DLN from 4THM immune, while CD200R1KO-derived DLN of EMT6 immune mice attenuated tumor invasion, despite inclusion of IL-6/IL-17 in the gel layer.

Conclusion

Multiple factors can regulate tumor invasion, including micro-environmental stromal elements, IL-6/IL-17, and signals from tumor-derived DLN cells.
Literatur
1.
Zurück zum Zitat Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200 Cancer Immunol. Immunotherapy. 2008;57:987–96.CrossRef Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200 Cancer Immunol. Immunotherapy. 2008;57:987–96.CrossRef
2.
Zurück zum Zitat Moreaux J, Veyrune JL, Reme T, DeVos J, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2008;366:117–22.CrossRefPubMed Moreaux J, Veyrune JL, Reme T, DeVos J, Klein B. CD200: a putative therapeutic target in cancer. Biochem Biophys Res Commun. 2008;366:117–22.CrossRefPubMed
3.
Zurück zum Zitat McWhirter JR, KretzRommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Nat Acad Sci USA. 2006;103:1041–6.CrossRefPubMed McWhirter JR, KretzRommel A, Saven A, et al. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc Nat Acad Sci USA. 2006;103:1041–6.CrossRefPubMed
4.
Zurück zum Zitat Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun. 2007;364:778–82.CrossRefPubMedPubMedCentral Kawasaki BT, Mistree T, Hurt EM, Kalathur M, Farrar WL. Co-expression of the tolerogenic glycoprotein, CD200, with markers for cancer stem cells. Biochem Biophys Res Commun. 2007;364:778–82.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Gorczynski RM, Chen Z, Diao J, et al. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat. 2010;123:405–15.CrossRefPubMed Gorczynski RM, Chen Z, Diao J, et al. Breast cancer cell CD200 expression regulates immune response to EMT6 tumor cells in mice. Breast Cancer Res Treat. 2010;123:405–15.CrossRefPubMed
6.
Zurück zum Zitat Gorczynski RM, Clark DA, Erin N, Khatri I. Role of CD200 in regulation of tumor invasion of EMT6 tumor cells in mice. Breast Cancer Res Treat. 2011;130:49–60.CrossRefPubMed Gorczynski RM, Clark DA, Erin N, Khatri I. Role of CD200 in regulation of tumor invasion of EMT6 tumor cells in mice. Breast Cancer Res Treat. 2011;130:49–60.CrossRefPubMed
7.
Zurück zum Zitat Erin N, Podnos A, Tanriover G, Duymus O, Cote E, Khatri I, Gorczynski RM. Bidirectional effect of CD200 on breast cancer development and tumor invasion with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene. 2014;34:3860.CrossRefPubMed Erin N, Podnos A, Tanriover G, Duymus O, Cote E, Khatri I, Gorczynski RM. Bidirectional effect of CD200 on breast cancer development and tumor invasion with ultimate outcome determined by tumor aggressiveness and a cancer-induced inflammatory response. Oncogene. 2014;34:3860.CrossRefPubMed
8.
Zurück zum Zitat De Visser KE, Eichten A, Lisa M. Coussens paradoxical roles of the immune system during cancer development. Nat Cancer Rev. 2006;6:24–37.CrossRef De Visser KE, Eichten A, Lisa M. Coussens paradoxical roles of the immune system during cancer development. Nat Cancer Rev. 2006;6:24–37.CrossRef
9.
Zurück zum Zitat Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic tumor invasion. Nature. 2015;527:329–35. https://doi.org/10.1038/nature15756.CrossRefPubMedPubMedCentral Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K, Wexler LH, Narendran A, Schwartz GK, Healey JH, Sandstrom P, Labori KJ, Kure EH, Grandgenett PM, Hollingsworth MA, de Sousa M, Kaur S, Jain M, Mallya K, Batra SK, Jarnagin WR, Brady MS, Fodstad O, Muller V, Pantel K, Minn AJ, Bissell MJ, Garcia BA, Kang Y, Rajasekhar VK, Ghajar CM, Matei I, Peinado H, Bromberg J, Lyden D. Tumour exosome integrins determine organotropic tumor invasion. Nature. 2015;527:329–35. https://​doi.​org/​10.​1038/​nature15756.CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, Baelde HJ, Monge M, Vos JB, de Boer HC, Quax PH, Rabelink TJ, van Zonneveld AJ. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med. 2009;13:1577–85.CrossRefPubMed van Solingen C, Seghers L, Bijkerk R, Duijs JM, Roeten MK, van Oeveren-Rietdijk AM, Baelde HJ, Monge M, Vos JB, de Boer HC, Quax PH, Rabelink TJ, van Zonneveld AJ. Antagomir-mediated silencing of endothelial cell specific microRNA-126 impairs ischemia-induced angiogenesis. J Cell Mol Med. 2009;13:1577–85.CrossRefPubMed
14.
Zurück zum Zitat Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–9.CrossRefPubMed Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with ‘antagomirs’. Nature. 2005;438:685–9.CrossRefPubMed
20.
Zurück zum Zitat Zhao P, Chen Y, Yue Z, Yuan Y, Wang X. Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway. Leuk Res. 2017;57:20–6.CrossRefPubMed Zhao P, Chen Y, Yue Z, Yuan Y, Wang X. Bone marrow mesenchymal stem cells regulate stemness of multiple myeloma cell lines via BTK signaling pathway. Leuk Res. 2017;57:20–6.CrossRefPubMed
21.
Zurück zum Zitat Zhu F, Khatri I, Spaner D, Gorczynski RM. An autologous tumor vaccine for CLL. Leuk Res. 2018: in press. Zhu F, Khatri I, Spaner D, Gorczynski RM. An autologous tumor vaccine for CLL. Leuk Res. 2018: in press.
22.
Zurück zum Zitat Podnos A, Clark DA, Erin N, Yu K, Gorczynski RM. Further evidence for a role of tumor CD200 expression in breast cancer tumor invasion: decreased tumor invasion in CD200R1KO mice or using CD200-silenced EMT6. Breast Cancer Res Treat. 2012;136:117–27.CrossRefPubMed Podnos A, Clark DA, Erin N, Yu K, Gorczynski RM. Further evidence for a role of tumor CD200 expression in breast cancer tumor invasion: decreased tumor invasion in CD200R1KO mice or using CD200-silenced EMT6. Breast Cancer Res Treat. 2012;136:117–27.CrossRefPubMed
27.
Zurück zum Zitat Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10:7157–62.CrossRefPubMed Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpé S, Vermeulen PB, Dirix LY. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res. 2004;10:7157–62.CrossRefPubMed
31.
Zurück zum Zitat Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL-6 secretion. Proc Natl Acad Sci USA. 2011;108:1397–402.CrossRefPubMed Iliopoulos D, Hirsch HA, Wang G, Struhl K. Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL-6 secretion. Proc Natl Acad Sci USA. 2011;108:1397–402.CrossRefPubMed
32.
Zurück zum Zitat Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, Lee DS. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous tumor invasion through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):79.CrossRef Oh K, Lee OY, Shon SY, Nam O, Ryu PM, Seo MW, Lee DS. A mutual activation loop between breast cancer cells and myeloid-derived suppressor cells facilitates spontaneous tumor invasion through IL-6 trans-signaling in a murine model. Breast Cancer Res. 2013;15(5):79.CrossRef
33.
Zurück zum Zitat Roy LD, Sahraei M, Schettini JL, Gruber HE, Besmer DM, Mukherjee P. Systemic neutralization of IL-17A significantly reduces breast cancer associated tumor invasion in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer. 2014;27(14):225. https://doi.org/10.1186/1471-2407-14-225.CrossRef Roy LD, Sahraei M, Schettini JL, Gruber HE, Besmer DM, Mukherjee P. Systemic neutralization of IL-17A significantly reduces breast cancer associated tumor invasion in arthritic mice by reducing CXCL12/SDF-1 expression in the metastatic niches. BMC Cancer. 2014;27(14):225. https://​doi.​org/​10.​1186/​1471-2407-14-225.CrossRef
37.
Zurück zum Zitat McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and tumor invasion. Nature Cell Biol. 2014;16:717–27.CrossRefPubMed McAllister SS, Weinberg RA. The tumour-induced systemic environment as a critical regulator of cancer progression and tumor invasion. Nature Cell Biol. 2014;16:717–27.CrossRefPubMed
38.
Zurück zum Zitat Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.CrossRefPubMed Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10:593–601.CrossRefPubMed
39.
Zurück zum Zitat Jiang S, Zhang H-W, Lu M-H, He X-H, Li Y, Gu H, et al. MicroRNA-155 Functions as an OncomiR in breast cancer by targeting the Suppressor of Cytokine Signaling 1 Gene. Cancer Res. 2010;70:3119–27.CrossRefPubMed Jiang S, Zhang H-W, Lu M-H, He X-H, Li Y, Gu H, et al. MicroRNA-155 Functions as an OncomiR in breast cancer by targeting the Suppressor of Cytokine Signaling 1 Gene. Cancer Res. 2010;70:3119–27.CrossRefPubMed
44.
Zurück zum Zitat Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin ML, Begum J, Baker AM, Amgheib A, Saif J, Perez M, Soriano J, Desco M, Gomez-Gaviro MV, Cusso L, Megias D, Aicher A, Heeschen C. The miR-25-93-106b cluster regulates tumor tumor invasion and immune evasion via modulation of CXCL12 and PD-L1. Mol Cancer. 2017;16:148. https://doi.org/10.1186/s12943-017-0718-4.CrossRef Cioffi M, Trabulo SM, Vallespinos M, Raj D, Kheir TB, Lin ML, Begum J, Baker AM, Amgheib A, Saif J, Perez M, Soriano J, Desco M, Gomez-Gaviro MV, Cusso L, Megias D, Aicher A, Heeschen C. The miR-25-93-106b cluster regulates tumor tumor invasion and immune evasion via modulation of CXCL12 and PD-L1. Mol Cancer. 2017;16:148. https://​doi.​org/​10.​1186/​s12943-017-0718-4.CrossRef
46.
Zurück zum Zitat Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013;32:303–15.CrossRefPubMedPubMedCentral Mao Y, Keller ET, Garfield DH, Shen K, Wang J. Stromal cells in tumor microenvironment and breast cancer. Cancer Metastasis Rev. 2013;32:303–15.CrossRefPubMedPubMedCentral
47.
Zurück zum Zitat Gorczynski RM, Zhu F, Chen Z, Kos O, Khatri I. A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice. Breast Cancer Res Treat. 2017;162:255–66.CrossRefPubMed Gorczynski RM, Zhu F, Chen Z, Kos O, Khatri I. A comparison of serum miRNAs influencing metastatic growth of EMT6 vs 4THM tumor cells in wild-type and CD200R1KO mice. Breast Cancer Res Treat. 2017;162:255–66.CrossRefPubMed
Metadaten
Titel
Characterization of an in vitro model system to explore control of tumor invasion of EMT6 and 4THM breast tumors by CD200:CD200R interactions
verfasst von
Reginald M. Gorczynski
Nuray Erin
Tahir Maqbool
Christopher P. Gorczynski
Laura Y. Gorczynski
Publikationsdatum
12.03.2018
Verlag
Springer Japan
Erschienen in
Breast Cancer / Ausgabe 5/2018
Print ISSN: 1340-6868
Elektronische ISSN: 1880-4233
DOI
https://doi.org/10.1007/s12282-018-0851-y

Weitere Artikel der Ausgabe 5/2018

Breast Cancer 5/2018 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.